TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12815786

Group type: EXPERIMENTAL
Intervention: MAG i.v. group (25 patients) received daily doses of 2.5 ml of 20% MgSO4 per each 500 ml of transfused fluids for 5 days (day of surgery + 4 days post-surgery)
Number of subjects: 67

Group type: COMPARATOR
Intervention: NORMO group (20 patients) with normal serum magnesium levels
Number of subjects: 67

Group type: COMPARATOR
Intervention: HYPO group (22 patients) who developed hypomagnesaemia postoperatively
Number of subjects: 67
Study: 9339388

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8170750

Group type: EXPERIMENTAL
Intervention: Visualization plus Danjeon breathing
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Danjeon breathing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 3952518

Group type: EXPERIMENTAL
Intervention: Prednimustine (PM)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Cyclophosphamide-vincristine-prednisolone (CVP)
Number of subjects: 217
Study: 11150431

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (200 mg/m² per cycle) with etoposide and bleomycin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard dose cisplatin (100 mg/m² per cycle) with etoposide and bleomycin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Initial Resection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Delayed Resection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Complete Resection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Partial Resection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Biopsy Only
Number of subjects: 74
Study: 31243790

Group type: COMPARATOR
Intervention: DS-1040 single ascending doses (50, 100, 200, or 400 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: DS-1040 multiple ascending doses (100 mg once daily, 200 mg once daily, or 150 mg twice daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DS-1040 single and multiple doses
Number of subjects: 56

Group type: COMPARATOR
Intervention: DS-1040
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 28446382

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 35
Study: 26575283

Group type: EXPERIMENTAL
Intervention: Support-giving condition (writing a supportive note to a friend)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (writing about their route to school/work)
Number of subjects: 0
Study: 24898233

Group type: EXPERIMENTAL
Intervention: Daily breakfast (≥700 kcal before 1100)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Extended fasting (0 kcal until 1200)
Number of subjects: 33
Study: 22358132

Group type: EXPERIMENTAL
Intervention: LAM plus adefovir (ADV) therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 53
Study: 20585300

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Concurrent Endurance and Resistance Training (CT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 37
Study: 17336025

Group type: EXPERIMENTAL
Intervention: Emotional disclosure intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Time management control condition
Number of subjects: 40
Study: 16244278

Group type: EXPERIMENTAL
Intervention: Bellows system (intervention group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Non-bellows system (control group)
Number of subjects: 113
Study: 12001038

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg; n=22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline placebo (n=19)
Number of subjects: 41
Study: 10449693

Group type: EXPERIMENTAL
Intervention: Active hormone preparations
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 7794146

Group type: EXPERIMENTAL
Intervention: Seminar on rational prescribing of antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seminar on rational prescribing of benzodiazepines
Number of subjects: 0
Study: 2244420

Group type: EXPERIMENTAL
Intervention: PDO by Tissucol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDO by Ethibloc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-occluded pancreases
Number of subjects: 0
Study: 340975

Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31564144

Group type: EXPERIMENTAL
Intervention: Cemented VEPE component
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional polyethylene (PE) component
Number of subjects: 42
Study: 29263353

Group type: EXPERIMENTAL
Intervention: 5-day intensive inpatient spa therapy (2 hr/day), exercise (30 min/day), and education (45 min/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study: 25837016

Group type: EXPERIMENTAL
Intervention: Intravenous plus oral pantoprazole therapy (n=252)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Oral pantoprazole alone (n=252)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 504
Study: 23600534

Group type: EXPERIMENTAL
Intervention: Autoset Resmed A‐CPAP
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Remstar Auto Respironics A‐CPAP
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both A‐CPAP devices
Number of subjects: 79
Study: 21355700

Group type: EXPERIMENTAL
Intervention: Four unannounced spaced clinical case-based tests (CCTs) over 2 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: One intermediate test at 6 weeks (Control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Final retention test identical to the pre-test at 2 months (both groups)
Number of subjects: 19
Study: 19156149

Group type: EXPERIMENTAL
Intervention: Intrapericardial bleomycin (BLM) at 15 mg, followed by additional i.p.c. BLM 10 mg every 48 hours.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Observation alone after drainage (Control group).
Number of subjects: 79
Study: 17573751

Group type: EXPERIMENTAL
Intervention: Clove oil 1% cream
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (stool softeners and lignocaine cream 5%)
Number of subjects: 55
Study: 15488040

Group type: EXPERIMENTAL
Intervention: 18 gauge (G) needle without filter
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 21 gauge (G) needle without filter
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 19G filtered needle
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison between 18G and 21G groups of 2-mL ampoules
Number of subjects: 54
Study: 11425836

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg on days 1, 3 and 5
Number of subjects: 60

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 60
Study: 9407576

Group type: EXPERIMENTAL
Intervention: Psychogeriatric intervention (multidisciplinary joint treatment by a psychogeriatric team)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Psychogeriatric intervention
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study: 8485530

Group type: EXPERIMENTAL
Intervention: Multivariate nonparametric tests based on ranks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual tests for carry-over effects and direct treatment effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate response analysis
Number of subjects: 0
Study: 3113243

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 31142067

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 1 mg/kg intravenously for half an hour before operation and lidocaine for periprostatic nerve block (PNB)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Normal saline combined with PNB
Number of subjects: 166
Study: 28248620

Group type: EXPERIMENTAL
Intervention: Anti-tobacco advertisements with disgust images
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anti-tobacco advertisements with smoking cues
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of smoking cues and disgust content
Number of subjects: 50
Study: 25909652

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 6 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham IMT protocol
Number of subjects: 29
Study: 22929086

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for suicidal older men
Number of subjects: 33

Group type: COMPARATOR
Intervention: Veterans Affairs Behavioral Health Laboratory recruitment
Number of subjects: 33
Study: 21554734

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief Strategic Therapy (BST)
Number of subjects: 0
Study: 18651544

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 3
Study: 16519637

Group type: EXPERIMENTAL
Intervention: Urgent haemorrhoidectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study: 14642022

Group type: EXPERIMENTAL
Intervention: 11-item KADS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Full-length KADS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Six-item KADS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Clinician-rated scales (CDRS-R, CGI, GAF)
Number of subjects: 106
Study: 10229902

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.05U/kg/day or a maximum of 3U/day s.c., reduced to 0.024±0.004U/kg/day due to side effects.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 8698357

Group type: EXPERIMENTAL
Intervention: r-hIFN-beta 1 x 10(6) IU/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r-hIFN-beta 33,000 IU/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2055059

Group type: EXPERIMENTAL
Intervention: Ventilatory rate at 8 cycles/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ventilatory rate at 16 cycles/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of ventilatory rates (8 and 16 cycles/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15 secs of apnea in patients
Number of subjects: 6
Study: 6852357

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone‐17,21‐dipropionate + 2% salicylic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone‐17,21‐dipropionate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% salicylic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31615800

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH) group (33°C≤T°C≤34°C)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Normothermia group (36°C≤T°C≤37°C)
Number of subjects: 334
Study: 26324729

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated nets (LLIN)
Number of subjects: 655
Study: 23323567

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg once daily in the morning
Number of subjects: 39

Group type: COMPARATOR
Intervention: Raloxifene 60 mg once daily in the evening
Number of subjects: 39
Study: 21112875

Group type: EXPERIMENTAL
Intervention: JUMP-in programme
Number of subjects: 2848

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 2848
Study: 19232035

Group type: EXPERIMENTAL
Intervention: Repaglinide (up to 6 mg/day, 2 mg three times a day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Acarbose (up to 300 mg/day, 100 mg three times a day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison of Acarbose vs Repaglinide
Number of subjects: 103
Study: 17402796

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly or every other week
Number of subjects: 1400
Study: 14985268

Group type: EXPERIMENTAL
Intervention: 40% l-menthol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ethanol (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% l-menthol during A fibre conduction blockade
Number of subjects: 10
Study: 12405569

Group type: EXPERIMENTAL
Intervention: 100 J rectilinear biphasic shocks
Number of subjects: 14

Group type: COMPARATOR
Intervention: 150 J monophasic damped sine shocks
Number of subjects: 14
Study: 9934380

Group type: EXPERIMENTAL
Intervention: Technically oriented style of care
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Practice style emphasizing patient activation
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Lower baseline patient health status
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Declined health status over the study period
Number of subjects: 509
Study: 7752175

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 40
Study: 2259980

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nonsealant (control)
Number of subjects: 43
Study: 7353342

Group type: EXPERIMENTAL
Intervention: Full-length cigarettes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three-quarter-length cigarettes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half-length cigarettes
Number of subjects: 10
Study: 6849210

Group type: EXPERIMENTAL
Intervention: gentamicin plus metronidazole
Number of subjects: 128

Group type: COMPARATOR
Intervention: gentamicin plus clindamycin
Number of subjects: 128
Study: 29679398

Group type: EXPERIMENTAL
Intervention: QQ follow-up group (instant messaging software)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional follow-up group
Number of subjects: 160
Study: 27203284

Group type: EXPERIMENTAL
Intervention: HPV vaccination awareness and education intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 192
Study: 24971433

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG) for 6 months, tapered over 18 months (total of 2 years)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Historical control group treated with h-ATG/CsA for 6 months, CsA discontinued at 6 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG)
Number of subjects: 102
Study: 23257009

Group type: EXPERIMENTAL
Intervention: Jinshuibao capsules (3 capsules three times a day for 2-3 courses of treatment, each course = 6 weeks)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Jinshuibao capsules
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 270
Study: 20973950

Group type: EXPERIMENTAL
Intervention: Sequential intervention (phone call, SMS, postal reminder)
Number of subjects: 2123

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Satisfaction survey with reminders
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of intervention
Number of subjects: 2123
Study: 18515690

Group type: EXPERIMENTAL
Intervention: Problem solving therapy-primary care
Number of subjects: 306

Group type: COMPARATOR
Intervention: Dietary education control
Number of subjects: 306
Study: 16052083

Group type: EXPERIMENTAL
Intervention: 1 mg TH9507
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 2 mg TH9507
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12771488

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tacalcitol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Petrolatum (placebo)
Number of subjects: 20
Study: 10329288

Group type: EXPERIMENTAL
Intervention: Syllable repetition
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phonation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Repetitive lip closure
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined tasks in a single session
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Separate scanning sessions for tasks
Number of subjects: 13
Study: 8725496

Group type: EXPERIMENTAL
Intervention: High retroperitoneal ligation of the left spermatic vein
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 51
Study: 1776889

Group type: EXPERIMENTAL
Intervention: Advice to reduce stimulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: No advice (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Advice to reduce stimulation for infants under 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: No advice for infants under 12 weeks (control)
Number of subjects: 27
Study: 6292443

Group type: EXPERIMENTAL
Intervention: Magnesium trisilicate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Kaolin
Number of subjects: 6
Study: 30525953

Group type: EXPERIMENTAL
Intervention: Probiotic mixture including Lactobacillus acidophilus GLA‐14 and Lactobacillus rhamnosus HN001 plus bovine lactoferrin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28409557

Group type: EXPERIMENTAL
Intervention: Silk garments (100% silk, DermaSilk or DreamSkin) worn for up to 6 months, supplied as three sets per participant.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (without silk garments).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Silk garments (100% silk).
Number of subjects: 300
Study: 25907003

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of solifenacin 6 mg plus TOCAS (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TOCAS monotherapy (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24919094

Group type: EXPERIMENTAL
Intervention: Royal jelly
Number of subjects: 103

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride and nystatin rinses (Control)
Number of subjects: 103
Study: 22411849

Group type: EXPERIMENTAL
Intervention: Erythropoietin (20,000 IU every 3 weeks, 40,000 IU every 3 weeks, and 40,000 IU every 2 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 16
Study: 19073788

Group type: EXPERIMENTAL
Intervention: Supplemental iron source (7.6 mg FeSO4 providing 0.9 mg 58Fe as FeSO4)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonheme food source (orange‐fleshed sweet potato: 1.4 mg native Fe)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Presence of food
Number of subjects: 18

Group type: COMPARATOR
Intervention: Absence of food
Number of subjects: 18
Study: 17093965

Group type: EXPERIMENTAL
Intervention: Oral midazolam (7.5 mg) 15 min before MRI
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intranasal midazolam (1 or 2 mg via nasal spray) immediately prior to MRI
Number of subjects: 72
Study: 15044206

Group type: EXPERIMENTAL
Intervention: Streptokinase (250,000 IU) instilled over 4.5 ± 2 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal saline instilled over 3 ± 1.3 days
Number of subjects: 53
Study: 11811113

Group type: EXPERIMENTAL
Intervention: Allicor 600 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9611361

Group type: EXPERIMENTAL
Intervention: Laryngeal mask anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endotracheal intubation anaesthesia
Number of subjects: 0
Study: 8147677

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/d
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg/d
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/d
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/d + Hydrochlorothiazide 12.5 mg/d
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/d + Hydrochlorothiazide 25 mg/d
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 3145000

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study: 31823152

Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg) plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Number of subjects: 114
Study: 30273821

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ad libitum diet (AL)
Number of subjects: 220
Study: 28744855

Group type: EXPERIMENTAL
Intervention: Active (stimulation on)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 16
Study: 26036333

Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 10

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 10
Study: 23426454

Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Mesalamine+Bifidobacterium infantis 35624
Number of subjects: 117
Study: 22177437

Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 U/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (3200 U/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 150
Study: 19249105

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS with placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Venlafaxine ER with sham rTMS
Number of subjects: 60
Study: 17130411

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 to 600 mg/day
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137